HBV Clinical Trial
Official title:
Effectiveness and Safety of Tenofovir Alafenamide for HBV Prophylaxis in HBV Negative Recipients Received Orthotopic Liver Transplant With HBcAb+ Donors
Liver transplantation is currently the only effective way to treat end-stage liver disease.The shortage of donor liver is still the major problem. Incidence of HBcAb+ varies between different regions. The HBcAb positive rate could be as high as 52% in China.HBcAb positive donor liver may enlarge donor pool and thus save ESLD patients. However, the use of HBcAb positive donor liver may induce HBV infection in hepatitis B negative recipient after liver transplantation. Tenofovir alafenamide (TAF) has better stability in plasma and higher liver targeting property in comparison with tenofovir (TDF), with an extra amide bond, which allows strong antiviral effect with much less doses and reducing the renal and bone injury. Our study intends to evaluate the efficacy and safety of HBV prophylaxis treatment of TAF in HBV negative patients after receiving HBcAb positive donor livers.
We intent to enroll 30 patients who are HBV negative but received HBcAb+ liver. Antiviral treatment with TAF(25mg/d,oral) will be started on the first day after liver transplantation. Post-operative HBV infection is defined with positive HBV marker (HBsAg) and/or positive HBV DNA after liver transplantation. Primary outcome will be evaluated at 48 weeks. All the patients will be followed up for another at least 1 year to evaluate the long term efficacy and safety of TAF. The primary endpoint is to calculate de novo HBV infection after liver transplantation when treating with TAF. Secondary endpoint is to evaluate the renal safety of TAF after liver transplantation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05442437 -
Clinical Study of hUC-MSCs Treating Decompensated Liver Cirrhosis With HBV
|
Early Phase 1 | |
| Completed |
NCT04519710 -
Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies
|
N/A | |
| Recruiting |
NCT04562051 -
Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients
|
||
| Recruiting |
NCT04683341 -
Tenofovir Alafenamide in HBV Related Decompensated Liver
|
Phase 4 | |
| Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
| Completed |
NCT02044068 -
Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women
|
N/A | |
| Completed |
NCT03239353 -
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04904835 -
Access HBV Assays - European Union (EU) Clinical Trial Protocol -
|
||
| Terminated |
NCT04059198 -
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
|
Phase 2 | |
| Not yet recruiting |
NCT05293158 -
Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study
|
N/A | |
| Not yet recruiting |
NCT05028322 -
Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen
|
Phase 2 | |
| Completed |
NCT02312531 -
Prevention for Mother-to-infant Transmission of HBV
|
N/A | |
| Not yet recruiting |
NCT01556815 -
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05786859 -
The Efficacy and Safety of Rifaximin Treatment
|
Early Phase 1 | |
| Recruiting |
NCT05951751 -
The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM)
|
N/A | |
| Not yet recruiting |
NCT06307808 -
Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination
|
||
| Completed |
NCT03149627 -
Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults
|
||
| Recruiting |
NCT04886336 -
The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients.
|
||
| Recruiting |
NCT04568265 -
A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
|
Phase 2 | |
| Terminated |
NCT02826018 -
A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
|
Phase 1 |